Pesquisar
Foreign companies intending to commercialize cosmetics, medical devices, or sanitizing products in Brazil must comply with ANVISA (Brazilian Health Regulatory Agency) requirements. One of the most important aspects of obtaining product registration or notification approval is the correct submission of documentation issued by the legal foreign manufacturer.
In this article, we explain the main documents required by ANVISA for imported products, the differences between cosmetics, medical devices, and sanitizing products, and how companies can avoid technical deficiencies and regulatory delays.
ANVISA requires evidence that the foreign manufacturer officially authorizes the Brazilian company to import, register, and commercialize the product in Brazil. The Agency also evaluates whether the product is manufactured according to internationally recognized quality, safety, and performance standards.
Incomplete, expired, or inconsistent documentation is one of the main reasons for technical requirements and rejection of regulatory submissions.
The Letter of Authorization is one of the most important documents for imported products. In this document, the legal manufacturer officially authorizes the Brazilian company to represent, import, register, and commercialize the product before ANVISA.
A specialized company usually provides the draft so your company only fill with some information to get it done.
For medical devices, ANVISA often requires the LOA to be apostilled or legalized.
The Free Sale Certificate demonstrates that the product is legally commercialized in its country of origin or another regulated market.
This document is commonly required for:
Depending on the product category, the FSC may need to be issued by a competent health authority, chamber of commerce, or recognized governmental body.
For many medical devices, ANVISA requires evidence of compliance with Good Manufacturing Practices.
Depending on the product risk classification, companies may need to submit:
Higher-risk medical devices are generally subject to stricter requirements.
Technical documentation is essential to demonstrate product safety, performance, and intended use.
The technical dossier may include:
Depending on the product category, ANVISA may also request:
Cosmetics usually have simpler regulatory pathways, especially lower-risk products. Higher-risk cosmetics may require more robust technical documentation, including safety and efficacy evidence.
Medical devices are subject to one of the most complex regulatory frameworks within ANVISA. Depending on the risk classification, the process may involve INMETRO certification, GMP certification, and extensive technical documentation.
Sanitizing products must demonstrate microbiological efficacy, stability, and chemical safety. Products with specific claims may require additional laboratory testing.
The most common regulatory issues include:
Companies that properly structure their regulatory documentation from the beginning significantly reduce the risk of technical deficiencies.
• Preliminary regulatory review of documents;
• Standardization of global documentation;
• Verification of validity dates and signatures;
• Adaptation of labeling to Brazilian requirements;
• Strategic assessment of product regulatory classification.
The approval of imported products by ANVISA depends directly on the quality of the documentation provided by the foreign manufacturer. Companies that invest in regulatory planning and document preparation can accelerate approvals, reduce deficiencies, and enter the Brazilian market more efficiently.
If your company plans to register cosmetics, medical devices, or sanitizing products in Brazil, working with a specialized regulatory consultancy can significantly reduce risks and improve the success rate of the process.